Ma P - Search Results

1

HLA and tumour immunology: immune escape, immunotherapy and immune-related adverse events.

Jiang N, Yu Y, Wu D, Wang S, Fang Y, Miao H, Ma P, Huang H, Zhang M, Zhang Y, Tang Y, Li N. Jiang N, et al. Among authors: ma p. J Cancer Res Clin Oncol. 2023 Feb;149(2):737-747. doi: 10.1007/s00432-022-04493-1. Epub 2023 Jan 20. J Cancer Res Clin Oncol. 2023. PMID: 36662304 Review.

2

[Prevention and control of multidrug-resistant organisms:guidelines vs practice].

Yu YT, Ma PL. Yu YT, et al. Among authors: ma pl. Zhonghua Yi Xue Za Zhi. 2019 Jul 2;99(25):1945-1948. doi: 10.3760/cma.j.issn.0376-2491.2019.25.008. Zhonghua Yi Xue Za Zhi. 2019. PMID: 31269597 Chinese.

3

Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors.

Wang S, Sun J, Chen K, Ma P, Lei Q, Xing S, Cao Z, Sun S, Yu Z, Liu Y, Li N. Wang S, et al. Among authors: ma p. BMC Med. 2021 Jun 11;19(1):140. doi: 10.1186/s12916-021-02006-4. BMC Med. 2021. PMID: 34112147 Free PMC article. Review.

4

The state of the art of bispecific antibodies for treating human malignancies.

Wang S, Chen K, Lei Q, Ma P, Yuan AQ, Zhao Y, Jiang Y, Fang H, Xing S, Fang Y, Jiang N, Miao H, Zhang M, Sun S, Yu Z, Tao W, Zhu Q, Nie Y, Li N. Wang S, et al. Among authors: ma p. EMBO Mol Med. 2021 Sep 7;13(9):e14291. doi: 10.15252/emmm.202114291. Epub 2021 Aug 24. EMBO Mol Med. 2021. PMID: 34431224 Free PMC article. Review.

5

An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020.

Wang S, Yang Q, Deng L, Lei Q, Yang Y, Ma P, Men Y, Yung BC, Lee RJ, Zhang M, Li N. Wang S, et al. Among authors: ma p. Drug Discov Today. 2022 May;27(5):1236-1250. doi: 10.1016/j.drudis.2021.12.021. Epub 2021 Dec 29. Drug Discov Today. 2022. PMID: 34971818 Free article. Review.

6

CEA-regulated Oncolytic Virus Anticancer Therapy: A Promising Strategy for Rare Solid Tumors.

Yang Y, Wang S, Ma P, Tang Q, Li Y, Fang Y, Zhu Q, Tao W, Zha Y, Li N. Yang Y, et al. Among authors: ma p. Curr Cancer Drug Targets. 2022;22(2):126-132. doi: 10.2174/1568009622666220202143852. Curr Cancer Drug Targets. 2022. PMID: 35114923

7

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials.

Wu D, Huang H, Zhang M, Li Z, Wang S, Yu Y, Fang Y, Jiang N, Miao H, Ma P, Tang Y, Li N. Wu D, et al. Among authors: ma p. J Hematol Oncol. 2022 Feb 8;15(1):16. doi: 10.1186/s13045-022-01227-1. J Hematol Oncol. 2022. PMID: 35135567 Free PMC article.

8

CAR-macrophage: An extensive immune enhancer to fight cancer.

Wang S, Yang Y, Ma P, Zha Y, Zhang J, Lei A, Li N. Wang S, et al. Among authors: ma p. EBioMedicine. 2022 Feb;76:103873. doi: 10.1016/j.ebiom.2022.103873. Epub 2022 Feb 10. EBioMedicine. 2022. PMID: 35152151 Free PMC article. No abstract available.

9

Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials.

Wang S, Yang Y, Ma P, Huang H, Tang Q, Miao H, Fang Y, Jiang N, Li Y, Zhu Q, Tao W, Zha Y, Li N. Wang S, et al. Among authors: ma p. Mol Ther Oncolytics. 2022 Feb 22;24:799-813. doi: 10.1016/j.omto.2022.02.019. eCollection 2022 Mar 17. Mol Ther Oncolytics. 2022. PMID: 35317518 Free PMC article. Review.

10

KRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients.

Wang S, Li Q, Ma P, Fang Y, Yu Y, Jiang N, Miao H, Tang Q, Yang Y, Xing S, Chen R, Yi X, Li N. Wang S, et al. Among authors: ma p. Front Mol Biosci. 2022 Mar 11;9:831382. doi: 10.3389/fmolb.2022.831382. eCollection 2022. Front Mol Biosci. 2022. PMID: 35359599 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,293 results

Search Page